Header Logo

Connection

MICHAEL ROBERTSON to Antineoplastic Agents, Immunological

Back to Details
This is a "connection" page, showing publications MICHAEL ROBERTSON has written about Antineoplastic Agents, Immunological.
MICHAEL ROBERTSON
Connection Strength
0.147
Antineoplastic Agents, Immunological
  1. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020 Sep; 7(9):e660-e670.
    View in: PubMed
    Score: 0.147
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.